Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old

NCT05518201 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Penile Cancer
Anal Cancer
PIN-1
PIN-2
PIN-3
AIN1
AIN2
AIN3
Genital Wart

Interventions

BIOLOGICAL: Placebo among 18-45 yrs
BIOLOGICAL: Placebo among 9-17 yrs

Sponsor

Shanghai Bovax Biotechnology Co., Ltd.